Suvretta Capital Management, Llc bought $10.3M of Veradermics (MANE)
Executed Feb 4, disclosed Feb 9, 5 days later, against a two-business-day limit.
Over the 21 trading sessions from the disclosed entry session (Feb 9), the stock returned +33.6% (delay-adjusted); from the execution session (Feb 4), +47.3%. Derived: entry at the session's open, exit at the close 20 sessions later.
Suvretta Capital Management, Llc (Director) filed 4 Form 4 reports as a reporting entity in the trailing twelve months (4 purchases, 0 sales, 2 filed past the two-business-day deadline), most often in BNTC. Across 4 priced purchase filings, the average 21-session return was +15.0% from execution and +9.0% from disclosure (delay-adjusted; derived). The largest single filing was $20.0M of BNTC (1,481,481 sh across 2 lots, as filed), executed Nov 7 2025.
Healthcare · Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthe…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→